Form 4: Novavax Director Charles W. Newton Reports Stock Option and RSU Grants

Director Charles W. Newton reports the acquisition of stock options and restricted stock units in Novavax, Inc.

Summary

• On April 25, 2025, Charles W. Newton, a director of Novavax, Inc., was granted stock options to purchase 42,840 shares of common stock at an exercise price of $6.70.
• These options vest in three equal installments on the first three anniversaries of the grant date, contingent upon continued service on the Board of Directors.
• Newton also received 28,560 restricted stock units (RSUs), each representing the right to receive one share of Novavax common stock.
• These RSUs also vest in three equal installments on the first three anniversaries of the grant date, subject to continued service on the Board of Directors.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of incentivizing a director with equity, suggesting confidence in the company's future. It's a neutral-positive signal.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the director.

Industry Context

Equity grants to directors are a common practice in the biotechnology industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, particularly in the biotech sector.
• Vesting schedules of three years are also typical to ensure continued service and alignment with long-term company goals.
• Comparable companies like Moderna or BioNTech also utilize similar equity-based compensation for their board members.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates

Keywords

Novavax, Director, Stock Options, RSUs, Charles W. Newton, Vesting, Form 4, NVAX